153 related articles for article (PubMed ID: 33508352)
1. Targeting of claudin-4 by Clostridium perfringens enterotoxin-conjugated polysialic acid nanoparticles for pancreatic cancer therapy.
Shim MK; Na J; Cho IK; Jang EH; Park J; Lee S; Kim JH
J Control Release; 2021 Mar; 331():434-442. PubMed ID: 33508352
[TBL] [Abstract][Full Text] [Related]
2. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin.
Michl P; Buchholz M; Rolke M; Kunsch S; Löhr M; McClane B; Tsukita S; Leder G; Adler G; Gress TM
Gastroenterology; 2001 Sep; 121(3):678-84. PubMed ID: 11522752
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase Cα inhibitor enhances the sensitivity of human pancreatic cancer HPAC cells to Clostridium perfringens enterotoxin via claudin-4.
Kyuno D; Kojima T; Ito T; Yamaguchi H; Tsujiwaki M; Takasawa A; Murata M; Tanaka S; Hirata K; Sawada N
Cell Tissue Res; 2011 Dec; 346(3):369-81. PubMed ID: 22160590
[TBL] [Abstract][Full Text] [Related]
4. Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy.
Pahle J; Menzel L; Niesler N; Kobelt D; Aumann J; Rivera M; Walther W
BMC Cancer; 2017 Feb; 17(1):129. PubMed ID: 28193196
[TBL] [Abstract][Full Text] [Related]
5. Tissue distribution and safety evaluation of a claudin-targeting molecule, the C-terminal fragment of Clostridium perfringens enterotoxin.
Li X; Saeki R; Watari A; Yagi K; Kondoh M
Eur J Pharm Sci; 2014 Feb; 52():132-7. PubMed ID: 24231339
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for
Vecchio AJ; Rathnayake SS; Stroud RM
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876770
[TBL] [Abstract][Full Text] [Related]
7. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer.
Cocco E; Casagrande F; Bellone S; Richter CE; Bellone M; Todeschini P; Holmberg JC; Fu HH; Montagna MK; Mor G; Schwartz PE; Arin-Silasi D; Azoudi M; Rutherford TJ; Abu-Khalaf M; Pecorelli S; Santin AD
BMC Cancer; 2010 Jul; 10():349. PubMed ID: 20598131
[TBL] [Abstract][Full Text] [Related]
8. Effects of Clostridium perfringens enterotoxin via claudin-4 on normal human pancreatic duct epithelial cells and cancer cells.
Yamaguchi H; Kojima T; Ito T; Kyuno D; Kimura Y; Imamura M; Hirata K; Sawada N
Cell Mol Biol Lett; 2011 Sep; 16(3):385-97. PubMed ID: 21573709
[TBL] [Abstract][Full Text] [Related]
9. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions.
Neesse A; Hahnenkamp A; Griesmann H; Buchholz M; Hahn SA; Maghnouj A; Fendrich V; Ring J; Sipos B; Tuveson DA; Bremer C; Gress TM; Michl P
Gut; 2013 Jul; 62(7):1034-43. PubMed ID: 22677720
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of Clostridium perfringens enterotoxin depends on the conditions of claudin-4 in ovarian carcinoma cells.
Tanaka S; Aoyama T; Ogawa M; Takasawa A; Murata M; Osanai M; Saito T; Sawada N
Exp Cell Res; 2018 Oct; 371(1):278-286. PubMed ID: 30142326
[TBL] [Abstract][Full Text] [Related]
11. Liposomes targeting the cancer cell-exposed receptor, claudin-4, for pancreatic cancer chemotherapy.
Bang C; Park MG; Cho IK; Lee DE; Kim GL; Jang EH; Shim MK; Yoon HY; Lee S; Kim JH
Biomater Res; 2023 May; 27(1):53. PubMed ID: 37237291
[TBL] [Abstract][Full Text] [Related]
12. Targeting claudin-overexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin.
Piontek A; Eichner M; Zwanziger D; Beier LS; Protze J; Walther W; Theurer S; Schmid KW; Führer-Sakel D; Piontek J; Krause G
Mol Oncol; 2020 Feb; 14(2):261-276. PubMed ID: 31825142
[TBL] [Abstract][Full Text] [Related]
13. Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer.
Kyuno D; Yamaguchi H; Ito T; Kono T; Kimura Y; Imamura M; Konno T; Hirata K; Sawada N; Kojima T
World J Gastroenterol; 2014 Aug; 20(31):10813-24. PubMed ID: 25152584
[TBL] [Abstract][Full Text] [Related]
14. A claudin 3 and claudin 4-targeted Clostridium perfringens protoxin is selectively cytotoxic to PSA-producing prostate cancer cells.
Romanov V; Whyard TC; Waltzer WC; Gabig TG
Cancer Lett; 2014 Sep; 351(2):260-4. PubMed ID: 24952257
[TBL] [Abstract][Full Text] [Related]
15. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin.
Litkouhi B; Kwong J; Lo CM; Smedley JG; McClane BA; Aponte M; Gao Z; Sarno JL; Hinners J; Welch WR; Berkowitz RS; Mok SC; Garner EI
Neoplasia; 2007 Apr; 9(4):304-14. PubMed ID: 17460774
[TBL] [Abstract][Full Text] [Related]
16. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin.
Ebihara C; Kondoh M; Hasuike N; Harada M; Mizuguchi H; Horiguchi Y; Fujii M; Watanabe Y
J Pharmacol Exp Ther; 2006 Jan; 316(1):255-60. PubMed ID: 16183701
[TBL] [Abstract][Full Text] [Related]
17. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier.
Sonoda N; Furuse M; Sasaki H; Yonemura S; Katahira J; Horiguchi Y; Tsukita S
J Cell Biol; 1999 Oct; 147(1):195-204. PubMed ID: 10508866
[TBL] [Abstract][Full Text] [Related]
18. Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer.
Gabig TG; Waltzer WC; Whyard T; Romanov V
Biochem Biophys Res Commun; 2016 Sep; 478(2):887-92. PubMed ID: 27520378
[TBL] [Abstract][Full Text] [Related]
19. Claudin-Targeted Suicide Gene Therapy for Claudin-Overexpressing Tumor Cells by Using Modified Clostridium perfringens Enterotoxin (CPE).
Beier LS; Piontek J; Piontek A; Protze J; Kobelt D; Walther W
Methods Mol Biol; 2022; 2521():173-188. PubMed ID: 35732998
[TBL] [Abstract][Full Text] [Related]
20. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors.
Yuan X; Lin X; Manorek G; Kanatani I; Cheung LH; Rosenblum MG; Howell SB
Mol Cancer Ther; 2009 Jul; 8(7):1906-15. PubMed ID: 19567823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
